Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | Director · CEO | April 14, 2022 | April 18, 2022 |
| INSULET CORPPODD · Entity 3516 | Director | May 16, 2018 | May 18, 2018 |
| THERMO FISHER SCIENTIFIC INC.TMO · Entity 2836 | Director | May 21, 2025 | May 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date April 14, 2022 · Filed April 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.69 · Expires 2031-03-01 | Direct | 170,989 |
Reported balance
After 2022-04-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-04-14 · Grant · Acquired 170,989 · Balance 170,989 F1: Reflects the vesting, upon the satisfaction of the performance criteria, of a portion of a performance-based stock option originally granted on March 2, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the vesting, upon the satisfaction of the performance criteria, of a portion of a performance-based stock option originally granted on March 2, 2021.
INSULET CORP
Report date May 16, 2018 · Filed May 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,783 |
Reported balance
After 2018-05-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-05-16 · Grant · Acquired 2,185 · Balance 7,783 F1: The 2,185 restricted stock units vest on April 30, 2019, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F2: Includes 3,098 restricted stock units granted on August 9, 2017, which vest one-half of the total units on August 9, 2018, one-quarter of the total units on August 9, 2019, and one-quarter of the total units on August 9, 2020, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The 2,185 restricted stock units vest on April 30, 2019, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.
F2: Includes 3,098 restricted stock units granted on August 9, 2017, which vest one-half of the total units on August 9, 2018, one-quarter of the total units on August 9, 2019, and one-quarter of the total units on August 9, 2020, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.
THERMO FISHER SCIENTIFIC INC.
Report date May 21, 2025 · Filed May 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,393 |
Reported balance
After 2025-05-21 transaction · row 1
1 source rowRow 1 · 2025-05-21 · Grant · Acquired 565 · Balance 3,393 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Patheon N.V.
Report date August 29, 2017 · Filed August 31, 2017
Section 16 reporting ended · disclosed 2017-08-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units (Ordinary Shares)SEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-08-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-08-29 · Other · Disposed 93,432 · Balance 906,858 F1: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. F2: This amount represents 93,432 unvested restricted stock units, each of which represented a contingent right to receive one Share of Issuer. Mr. Mullen's employment was terminated by the Issuer immediately following the time of the closing of the tender offer and, pursuant to the terms of the amendment to the Patheon N.V. Omnibus Incentive Plan executed as required by the Purchase Agreement, each unvested restricted stock unit award was cancelled and converted into a cash payment equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit. Row 2 · 2017-08-29 · Other · Disposed 906,858 · Balance 0 F3: This amount represents 906,858 outstanding restricted stock unit awards in respect of Shares that were subject, in whole or in part, to vesting based on the achievement of one or more performance goals (each, a "PSU"), whether vested or unvested. Pursuant to the terms of the Purchase Agreement, 462,177 PSUs were automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to required tax withholding), equal to the product of (i) $35.00 multiplied by (ii) the total number of Shares subject to such PSU award as of immediately prior to the closing of the tender offer (which, in the case of PSUs, was determined based on the actual achievement of performance conditions in accordance with the terms of the award). The remaining 444,681 PSUs were automatically cancelled and forfeited for no consideration in accordance with the terms of the Purchase Agreement and the PSU award. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Patheon Holdco Cooperatief U.A. on behalf of the reporting person | 0 |
Reported balance
After 2017-08-29 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2017-08-29 · Other · Disposed 2,615,089 · Balance 0 F1: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. F4: This amount represents ordinary shares held by Patheon Holdco Cooperatief U.A. on behalf of the reporting person. Such Shares were disposed of by Patheon Holdco Cooperatief U.A. pursuant to the tender offer for $35.00 per Share. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.49 | Direct | 0 |
Reported balance
After 2017-08-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-08-29 · Disposition to issuer · Disposed 242,885 · Balance 0 F5: The terms of the Option awards provide that options vest in three equal installments on each anniversary of the grant date of March 23, 2017. Mr. Mullen's employment was terminated by the Issuer immediately following the time of the closing of the tender offer and, pursuant to the terms of the amendment to the Patheon N.V. Omnibus Incentive Plan executed as required by the Purchase Agreement, each unvested option was cancelled and converted into a cash payment equal to the product of (x) the excess of $35.00 over the per Share exercise price of the option, multiplied by (y) the number of Shares subject to the option (rounded down the nearest whole share). |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher.
F2: This amount represents 93,432 unvested restricted stock units, each of which represented a contingent right to receive one Share of Issuer. Mr. Mullen's employment was terminated by the Issuer immediately following the time of the closing of the tender offer and, pursuant to the terms of the amendment to the Patheon N.V. Omnibus Incentive Plan executed as required by the Purchase Agreement, each unvested restricted stock unit award was cancelled and converted into a cash payment equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit.
F3: This amount represents 906,858 outstanding restricted stock unit awards in respect of Shares that were subject, in whole or in part, to vesting based on the achievement of one or more performance goals (each, a "PSU"), whether vested or unvested. Pursuant to the terms of the Purchase Agreement, 462,177 PSUs were automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to required tax withholding), equal to the product of (i) $35.00 multiplied by (ii) the total number of Shares subject to such PSU award as of immediately prior to the closing of the tender offer (which, in the case of PSUs, was determined based on the actual achievement of performance conditions in accordance with the terms of the award). The remaining 444,681 PSUs were automatically cancelled and forfeited for no consideration in accordance with the terms of the Purchase Agreement and the PSU award.
F4: This amount represents ordinary shares held by Patheon Holdco Cooperatief U.A. on behalf of the reporting person. Such Shares were disposed of by Patheon Holdco Cooperatief U.A. pursuant to the tender offer for $35.00 per Share.
F5: The terms of the Option awards provide that options vest in three equal installments on each anniversary of the grant date of March 23, 2017. Mr. Mullen's employment was terminated by the Issuer immediately following the time of the closing of the tender offer and, pursuant to the terms of the amendment to the Patheon N.V. Omnibus Incentive Plan executed as required by the Purchase Agreement, each unvested option was cancelled and converted into a cash payment equal to the product of (x) the excess of $35.00 over the per Share exercise price of the option, multiplied by (y) the number of Shares subject to the option (rounded down the nearest whole share).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2025 Filed May 22, 2025 20:45 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 565 | $0.00 | $0.00 |
DisclosureSEC source: 0000097745-25-000059 · form4.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,393 Read SEC document |
| May 22, 2024 Filed May 23, 2024 20:06 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 339 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016371 · form4.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,828 Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:30 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 392 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016992 · form4.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,489 Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:23 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 369 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015287 · form4.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,097 Read SEC document |
| April 14, 2022 Filed Apr 18, 2022 16:15 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 170,989 | $0.00 Strike: $45.69 | $0.00 |
DisclosureSEC source: 0001415889-22-004098 · form4-04182022_040401.xml · derivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,989 Underlying: Common Stock · 170,989 shares Expires 2031-03-01 F1 · derivative.exercise_date: Reflects the vesting, upon the satisfaction of the performance criteria, of a portion of a performance-based stock option originally granted on March 2, 2021. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 16:23 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 18,252 | $26.95 | $491,979.01 |
DisclosureSEC source: 0001179110-22-000112 · edgar.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,898 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on March 4, 2021, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 22, 2021. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 16:09 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 36,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-011223 · edgar.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,150 F1 · kind: Reflects the vesting, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on March 2, 2021. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 16:16 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 13,805 | $38.03 | $525,033.14 |
DisclosureSEC source: 0001179110-21-009557 · edgar.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,673 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on March 4, 2021, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 30, 2021. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 16:20 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 36,478 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-009149 · edgar.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,478 F1 · kind: Reflects the vesting, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on March 2, 2021. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 16:20 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 170,989 | $0.00 Strike: $45.69 | $0.00 |
DisclosureSEC source: 0001179110-21-006780 · edgar.xml · derivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,989 Underlying: Common Stock · 170,989 shares Expires 2031-03-01 F1 · derivative.exercise_date: Reflects the vesting, upon the achievement of a specified organizational milestone, of a portion of a performance-based stock option originally granted on March 2, 2021. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:09 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 438 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-017562 · form4.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,728 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 16:17 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 196,637 | $0.00 Strike: $45.69 | $0.00 |
DisclosureSEC source: 0001179110-21-002869 · edgar.xml · derivative · entry 2 MULLEN JAMES C · CIK 0001226288 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,637 Underlying: Common Stock · 196,637 shares Expires 2031-03-01 F2 · derivative.exercise_date: This option was granted on March 2, 2021 and is scheduled to vest as to one-third of the shares underlying the option when the closing price of the Issuer's common stock, as reported on the Nasdaq Global Select Market, has for 15 consecutive trading days in the five year period following the grant date equaled or exceeded $80.00, $100.00 and $120.00 per share, respectively. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 16:17 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | PurchaseCommon Stock | 25,000 | $46.27 | $1,156,800.00 |
DisclosureSEC source: 0001179110-21-002869 · edgar.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $46.27 to $46.44. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 16:20 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $27.49 | $0.00 |
DisclosureSEC source: 0001179110-20-007280 · edgar.xml · derivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2030-06-09 F1 · derivative.exercise_date: This option was granted on June 10, 2020 and is scheduled to vest in full on June 10, 2021. Read SEC document |
| May 20, 2020 Filed May 21, 2020 20:20 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 572 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-017550 · form4.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,290 Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:29 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $21.74 | $0.00 |
DisclosureSEC source: 0001179110-19-007680 · edgar.xml · derivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2029-06-11 F1 · derivative.exercise_date: This option was granted on June 12, 2019 and is scheduled to vest in full on June 12, 2020. Read SEC document |
| May 22, 2019 Filed May 23, 2019 20:39 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 718 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-019648 · form4.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718 Read SEC document |
| May 18, 2018 Filed May 22, 2018 17:28 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | PurchaseCommon Stock | 10,000 | $38.03 | $380,252.00 |
DisclosureSEC source: 0001179110-18-007362 · edgar.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $37.72 to $38.06. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 16, 2018 Filed May 18, 2018 21:49 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 2,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-018177 · form4.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,783 F1 · shares: The 2,185 restricted stock units vest on April 30, 2019, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F2 · balance_after: Includes 3,098 restricted stock units granted on August 9, 2017, which vest one-half of the total units on August 9, 2018, one-quarter of the total units on August 9, 2019, and one-quarter of the total units on August 9, 2020, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 17:25 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 23,076 | $0.00 Strike: $33.18 | $0.00 |
DisclosureSEC source: 0001179110-18-004894 · edgar.xml · derivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,076 Underlying: Common Stock · 23,076 shares Expires 2028-03-26 F1 · derivative.exercise_date: This option was granted on March 27, 2018 and is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on March 27, 2019 through March 27, 2021. Read SEC document |
| November 13, 2017 Filed Nov 14, 2017 23:03 UTC | INSULET CORP PODD · Entity 3516 | PurchaseCommon Stock | 2,500 | $67.45 | $168,632.75 |
DisclosureSEC source: 0001127602-17-032107 · form4.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,598 F1 · price: The price reported represents the weighted average purchase price of the shares purchased. The shares were purchased at varying prices in the range of $67.32 to $67.59. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 3,098 restricted stock units granted on August 9, 2017, which vest one-half of the total units on August 9, 2018, one-quarter of the total units on August 9, 2019, and one-quarter of the total units on August 9, 2020, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 18:26 UTC | Patheon N.V. PTHN · Entity 173467 | Disposition to issuerOptions (Right to Buy) · Derivative | 242,885 | Not disclosed Strike: $26.49 | Not disclosed |
DisclosureSEC source: 0001209191-17-050942 · doc4.xml · derivative · entry 4 MULLEN JAMES C · CIK 0001226288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 242,885 shares Expires not disclosed F5 · price: The terms of the Option awards provide that options vest in three equal installments on each anniversary of the grant date of March 23, 2017. Mr. Mullen's employment was terminated by the Issuer immediately following the time of the closing of the tender offer and, pursuant to the terms of the amendment to the Patheon N.V. Omnibus Incentive Plan executed as required by the Purchase Agreement, each unvested option was cancelled and converted into a cash payment equal to the product of (x) the excess of $35.00 over the per Share exercise price of the option, multiplied by (y) the number of Shares subject to the option (rounded down the nearest whole share). F5 · derivative.exercise_date: The terms of the Option awards provide that options vest in three equal installments on each anniversary of the grant date of March 23, 2017. Mr. Mullen's employment was terminated by the Issuer immediately following the time of the closing of the tender offer and, pursuant to the terms of the amendment to the Patheon N.V. Omnibus Incentive Plan executed as required by the Purchase Agreement, each unvested option was cancelled and converted into a cash payment equal to the product of (x) the excess of $35.00 over the per Share exercise price of the option, multiplied by (y) the number of Shares subject to the option (rounded down the nearest whole share). F5 · derivative.expiration_date: The terms of the Option awards provide that options vest in three equal installments on each anniversary of the grant date of March 23, 2017. Mr. Mullen's employment was terminated by the Issuer immediately following the time of the closing of the tender offer and, pursuant to the terms of the amendment to the Patheon N.V. Omnibus Incentive Plan executed as required by the Purchase Agreement, each unvested option was cancelled and converted into a cash payment equal to the product of (x) the excess of $35.00 over the per Share exercise price of the option, multiplied by (y) the number of Shares subject to the option (rounded down the nearest whole share). Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 18:26 UTC | Patheon N.V. PTHN · Entity 173467 | OtherOrdinary Shares | 2,615,089 | $35.00 | $91,528,115.00 |
DisclosureSEC source: 0001209191-17-050942 · doc4.xml · nonDerivative · entry 3 MULLEN JAMES C · CIK 0001226288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Patheon Holdco Cooperatief U.A. on behalf of the reporting person Disclosed balance after: 0 F1 · kind: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. F4 · shares: This amount represents ordinary shares held by Patheon Holdco Cooperatief U.A. on behalf of the reporting person. Such Shares were disposed of by Patheon Holdco Cooperatief U.A. pursuant to the tender offer for $35.00 per Share. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 18:26 UTC | Patheon N.V. PTHN · Entity 173467 | OtherRestricted Stock Units (Ordinary Shares) | 906,858 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-050942 · doc4.xml · nonDerivative · entry 2 MULLEN JAMES C · CIK 0001226288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · kind: This amount represents 906,858 outstanding restricted stock unit awards in respect of Shares that were subject, in whole or in part, to vesting based on the achievement of one or more performance goals (each, a "PSU"), whether vested or unvested. Pursuant to the terms of the Purchase Agreement, 462,177 PSUs were automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to required tax withholding), equal to the product of (i) $35.00 multiplied by (ii) the total number of Shares subject to such PSU award as of immediately prior to the closing of the tender offer (which, in the case of PSUs, was determined based on the actual achievement of performance conditions in accordance with the terms of the award). The remaining 444,681 PSUs were automatically cancelled and forfeited for no consideration in accordance with the terms of the Purchase Agreement and the PSU award. F3 · shares: This amount represents 906,858 outstanding restricted stock unit awards in respect of Shares that were subject, in whole or in part, to vesting based on the achievement of one or more performance goals (each, a "PSU"), whether vested or unvested. Pursuant to the terms of the Purchase Agreement, 462,177 PSUs were automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to required tax withholding), equal to the product of (i) $35.00 multiplied by (ii) the total number of Shares subject to such PSU award as of immediately prior to the closing of the tender offer (which, in the case of PSUs, was determined based on the actual achievement of performance conditions in accordance with the terms of the award). The remaining 444,681 PSUs were automatically cancelled and forfeited for no consideration in accordance with the terms of the Purchase Agreement and the PSU award. F3 · price: This amount represents 906,858 outstanding restricted stock unit awards in respect of Shares that were subject, in whole or in part, to vesting based on the achievement of one or more performance goals (each, a "PSU"), whether vested or unvested. Pursuant to the terms of the Purchase Agreement, 462,177 PSUs were automatically cancelled and converted into the right to receive an amount in cash (without interest and subject to required tax withholding), equal to the product of (i) $35.00 multiplied by (ii) the total number of Shares subject to such PSU award as of immediately prior to the closing of the tender offer (which, in the case of PSUs, was determined based on the actual achievement of performance conditions in accordance with the terms of the award). The remaining 444,681 PSUs were automatically cancelled and forfeited for no consideration in accordance with the terms of the Purchase Agreement and the PSU award. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 18:26 UTC | Patheon N.V. PTHN · Entity 173467 | OtherRestricted Stock Units (Ordinary Shares) | 93,432 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-050942 · doc4.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 906,858 F1 · kind: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. F2 · shares: This amount represents 93,432 unvested restricted stock units, each of which represented a contingent right to receive one Share of Issuer. Mr. Mullen's employment was terminated by the Issuer immediately following the time of the closing of the tender offer and, pursuant to the terms of the amendment to the Patheon N.V. Omnibus Incentive Plan executed as required by the Purchase Agreement, each unvested restricted stock unit award was cancelled and converted into a cash payment equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit. F1 · price: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 20:40 UTC | INSULET CORP PODD · Entity 3516 | GrantStock Option (Right to Buy) · Derivative | 4,126 | $0.00 Strike: $53.80 | $0.00 |
DisclosureSEC source: 0001127602-17-025505 · form4.xml · derivative · entry 2 MULLEN JAMES C · CIK 0001226288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,126 Underlying: Common Stock · 4,126 shares Expires 2027-08-09 F2 · derivative.exercise_date: This option is subject to a three-year vesting period with 50% of the total award vesting on the first anniversary of the date of grant and 25% of the total award vesting on each of the second and third anniversaries of the date of grant, subject to continued service as a director or consultant. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 20:40 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 3,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-025505 · form4.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,098 F1 · balance_after: The 3,098 restricted stock units vest 50% of the total award on the first anniversary of the date of grant and 25% of the total award on each of the second and third anniversaries of the date of grant, subject to continued service as a director or consultant. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 15:22 UTC | Patheon N.V. PTHN · Entity 173467 | GrantOptions (Right to Buy) · Derivative | 242,885 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001643848-17-000023 · wf-form4_149064255564125.xml · derivative · entry 2 MULLEN JAMES C · CIK 0001226288 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,885 Underlying: Options (Right to Buy) · 242,885 shares Expires not disclosed F2 · derivative.exercise_date: The options vest in three equal installments on each anniversary of the grant date of March 23, 2017. F2 · derivative.expiration_date: The options vest in three equal installments on each anniversary of the grant date of March 23, 2017. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 15:22 UTC | Patheon N.V. PTHN · Entity 173467 | GrantRestricted Stock Units (Ordinary Shares) | 93,432 | $0.00 | $0.00 |
DisclosureSEC source: 0001643848-17-000023 · wf-form4_149064255564125.xml · nonDerivative · entry 1 MULLEN JAMES C · CIK 0001226288 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,290 F1 · shares: The restricted stock units vest in three equal installments on each anniversary of the grant date of March 23, 2017. Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.